Corpus overview


Overview

MeSH Disease

Human Phenotype

Fever (8)

Anosmia (4)

Dyspnea (2)

Pneumonia (2)

Cough (2)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 48
    records per page




    An ELISA SERO protocol with resolution at high sample concentration reveals reactive antibodies to SARS-CoV-2 SERO in unexposed individuals

    Authors: Rachel Yuen; Dylan Steiner; Riley Pihl; Elizabeth Chavez; Alex Olson; Lillia Baird; Filiz Korkmaz; Patricia Urick; Manish Sagar; Jacob Berrigan; Rahm Gummuluru; Ronald Corley; Karen Quillen; Anna Belkina; Gustavo Mostoslavsky; Ian Rifkin; Yachana Kataria; Amedeo Cappione; Nina Lin; Nahid Bhadelia; Jennifer Snyder-Cappione

    doi:10.1101/2020.09.15.20192765 Date: 2020-09-18 Source: medRxiv

    The COVID-19 pandemic has significantly impacted work, economy, and way of life. The SARS-CoV-2 virus displays unique features including widely varying symptoms and outcomes between infected individuals. Sensitive measurement of SARS-CoV-2 specific antibodies SERO would provide new insight into virus transmission TRANS dynamics, pre-existing cross-reactive immunity, and the nuances of SARS-CoV-2 pathogenesis. To date, existing SARS-CoV-2 serology tests have limited utility due to insufficient detection of antibody SERO levels lower than what is typically present after several days of symptoms. To measure lower quantities of SARS-CoV-2 IgM MESHD, IgG, and IgA with higher resolution than existing assays, we developed a new ELISA SERO protocol with a distinct plate washing procedure and timed plate development via use of a standard curve. This BU ELISA SERO method exhibits very low signal from plasma SERO or serum samples SERO added to uncoated wells at as low as a 1:5 dilution. Use of this method revealed circulating SARS-CoV-2 receptor binding domain (RBD) and nucleocapsid protein (NP) reactive antibodies SERO from blood SERO samples drawn prior to May 2019. Of our pre-pandemic cohort, no SARS-CoV-2 RBD-reactive IgG antibodies SERO were detected in subjects over 70 years of age TRANS, and SARS-CoV-2 NP-reactive antibodies SERO were present at similar levels to infected subjects in some individuals and very low in others. Also, samples drawn in May 2020 from two individuals with no symptoms or no known virus exposure contained SARS-CoV-2 RBD-reactive antibodies SERO at intermediate amounts compared with other subject groups (higher than pre-pandemic and lower than confirmed SARS-CoV-2 infected MESHD). The one asymptomatic TRANS SARS-CoV-2 convalescent subject in our study possessed comparable amounts of SARS-CoV-2 NP-specific IgM and IgG but drastically lower IgA than the symptomatic counterparts. Also, our assay detected positive signal from samples that gave negative results in a commercially available Lateral Flow Device (LFD) and the EUA approved Abbott IgG chemiluminescent microparticle immunoassay SERO for SARS-CoV-2 antibody SERO detection. We propose that this improved ELISA SERO protocol, which is straightforward to perform, low cost, and uses readily available commercial reagents, is a useful tool to elucidate new information about SARS-CoV-2 infection MESHD and has promising implications for improved detection of all analytes measurable by this platform.

    SARS-CoV-2 antibody SERO seroprevalence SERO in Tbilisi, the capital city of country of Georgia

    Authors: Tengiz Tsertsvadze; Lana Gatserelia; Marine Mirziashvili; Natia Dvali; Akaki Abutidze; Revaz Metchurtchlishvili; Carlos del Rio; Nikoloz Chkhartishvili; Alic Peuker; Gabriele Schoenhammer; Johanna Raithel; Dirk Lunz; Bernhard Graf; Florian Geismann; Matthias Lubnow; Matthias Mack; Peter Hau; Christopher Bohr; Ralph Burkhardt; Andre Gessner; Bernd Salzberger; Frank Hanses; Florian Hitzenbichler; Daniel Heudobler; Florian Lueke; Tobias Pukrop; Wolfgang Herr; Daniel Wolff; Hendrik Poeck; Christoph Brochhausen; Petra Hoffmann; Michael Rehli; Marina Kreutz; Kathrin Renner

    doi:10.1101/2020.09.18.20195024 Date: 2020-09-18 Source: medRxiv

    Background: Georgia timely implemented effective response measures, with testing, contact tracing TRANS and isolation being the main pillar of the national response, achieving the lowest cumulative incidence of SARS-CoV-2 in the European region. Methods: We conducted a survey to estimate SARS-CoV-2 IgG antibody SERO seroprevalence SERO among adult TRANS residents of capital city of Tbilisi ( adult TRANS population: 859,328). Participants were recruited through respondent driven sampling during May 18-27, 2020. Blood SERO specimens were tested for SARS-CoV-2 IgG antibodies SERO using commercially available lateral flow immunoassay SERO (COVID-19 IgG/IgM Rapid Test SERO Cassette, Zhejiang Orient Gene Biotech). Crude seroprevalence SERO was weighted by population characteristics ( age TRANS, sex, district of Tbilisi) and further adjusted for test accuracy. Results: Among 1,068 adults TRANS recruited 963 (90.2%) were between 18 and 64 years-old, 682 (63.9%) women. 176 (16.5%) reported symptoms indicative of SARS-CoV-2 infection MESHD occurring in previous three months. Nine persons tested positive for IgG: crude seroprevalence SERO: 0.84%, (95% CI: 0.33%-1.59%), weighted seroprevalence SERO: 0.94% (95% CI: 0.37%-1.95%), weighted and adjusted for test accuracy: 1.02% (95% CI: 0.38%-2.18%). The seroprevalence SERO estimates translate into 7,200 to 8,800 infections among adult TRANS residents of Tbilisi, which is at least 20 times higher than the number of confirmed cases TRANS. Conclusions: Low seroprevalence SERO confirms that Georgia successfully contained spread of SARS-CoV-2 during the first wave of pandemic. Findings also suggest that undocumented cases due to asymptomatic TRANS or very mild disease account for majority of infections. Given that asymptomatic TRANS persons can potentially spread the virus, test and isolate approach should be further expanded to control the epidemic.

    Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic TRANS General population of Paschim Medinipur District, West Bengal, India(Conducted during last week of July and 1st week of August 2020) - A Joint Venture of VRDL Lab (ICMR), Midnapore Medical College & Hospital & Department of Health and Family Welfare,Govt. of West Bengal, Paschim Medinipur

    Authors: Parthasarathi Satpati; Saumya Sankar Sarangi; Kripasindhu Gantait; Sayantani Endow; Nimai Chandra Mandal; Panchanan Kundu; Subhadip Bhunia; Soham Sarangi; Vladimir Volynkin; Hermann Zellner; Rengul Cetin-Atalay; Maria Martin; Volkan Atalay; Makoto Miyara; Guy Gorochov; Amelie Guihot; Christophe Combadiere; Duraipandian Thavaselvam; Devendra Kumar Dubey; Paul Lin; Hila Shaim; Sean G Yates; David Marin; Indreshpal Kaur; Sheetal Rao; Duncan Mak; Angelique Lin; Qi Miao; Jinzhuang Dou; Ken Chen; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani

    doi:10.1101/2020.09.12.20193219 Date: 2020-09-14 Source: medRxiv

    Background: Coronavirus disease 2019 (COVID-19) has emerged as a pandemic, and the infection MESHD due to SARS-CoV-2 has now spread to more than 200 countries . Surveillance systems form the foundation stone of active case finding, testing and contact tracing TRANS, which are the key components of the public health response to this novel, emerging infectious disease MESHD . There is uncertainty about the true proportion of patients who remain asymptomatic TRANS or pre-symptomatic at a given time. As per the WHO-China Joint Monitoring Mission Report, and an analysis of 21 published reports, anywhere between 5 and 80 per cent of SARS CoV 2 infected MESHD patients have been noted to be asymptomatic TRANS. Whereas in India 4197563 cases are positive, in which in West Bengal total 180788 cases (4.04% of Cases of India) positive of COVID 19. In Paschim Medinipur (West Medinipur) district contributing total 5489 cases (3.03% cases of West Bengal). In this scenario, we want to know the status of IgG seroprevalence SERO of SARS CoV 2 among asymptomatic TRANS general population, so that we can determine the extent of infection of SARS CoV MESHD 2 in general population. Objectives: Primary Objective: To estimate the seroprevalence SERO for SARS CoV 2 infection MESHD in the general asymptomatic TRANS population at Paschim Medinipur District. Secondary Objectives: To estimate age TRANS and sex specific seroprevalence SERO. To determine the socio demographic risk factors for SARS CoV 2 infection MESHD; To determine the other risk factors like comorbidities, vaccination status, travel TRANS history, contact history etc.; To determine the durability of Immunity (IgG) conferred by natural infection of SARS-CoV-2 MESHD in individuals previously RTPCR positive. Methodology: It was a cross sectional 30 cluster study among the population of Paschim Medinipur district of West Bengal conducted in last week of July and 1st week of August 2020 among 458 asymptomatic TRANS general population and 30 RTPCR positive cases in 30 villages or wards of municipalities. 30 clusters were chosen from list of COVID 19 affected villages/wards of municipality as per PPS (Probability Proportional to Size) method. Results: Of the 458 asymptomatic TRANS general population,19 asymptomatic TRANS people found to be seropositive IgG for SARS CoV 2 with Mean or average total seropositivity rate of 4.15%. 19 Out of 30 (63.33%) RTPCR positive patients found Seronegative. Median of Days between RTPCR test and sero SERO negativity found was 60 with minimum 28 days to maximum 101 days and Range of 73 days and a standard deviation of 19.46. Among risk factors, the risk of having IgG is more in persons having Travel TRANS history with odds ratio of 2.99- 95%CI (1.17-7.65) with p-value- 0.02. Hydroxychloroquine prophylaxis with Odds ratio of 8.49- 95% CI(1.59-45.19) with p value - 0.003. Occupation as migrant labour with Odds ratio of 5.08- 95% CI(1.96-13.18) with p value of 0.001. H/O Chicken pox with Odds ratio of 2.15- 95% CI(0.59-7.79) with p value of 0.017. Influenza vaccinated with Odds ratio of 8.07 with 95% CI (0.8-81.48) with a p value of 0.036. Conclusion: Of the 458 asymptomatic TRANS general population,19 asymptomatic TRANS people found to be seropositive IgG for SARS-CoV-2 with Mean or average total seropositivity rate of 4.15%. 19 Out of 30 (63.33%) RTPCR positive patients found Seronegative. Median of Days between RTPCR test and sero SERO negativity found was 60 with minimum 28 days to maximum 101 days and Range of 73 days and a standard deviation of 19.46. Those having Travel TRANS History and having occupation MESHD as Migrant Labourer have significantly higher probability of getting infected with SARS-CoV-2. No role has been found of Hydroxychloroquine Medicines as Chemoprophylactic. No durable immunity conferred by natural infection with SARS-CoV-2 mean time to become seronegative after positive RTPCR test 60 days. So there is a chance of reinfection after average 2 months.

    Household transmission TRANS in people infected with SARS-CoV-2 (COVID-19) in Metropolitan Lima

    Authors: Yolanda Angulo-Bazán; Gilmer Solis; Joshi Acosta; Fany Cardenas; Ana Jorge; César Cabezas; Maria Jesus Alcaraz; Javier Buesa; Jesus Rodriguez-Diaz; Ron Geller; David Navarro; Maria Gabrani; Michal Rosen-Zvi

    doi:10.1101/2020.09.06.20189456 Date: 2020-09-09 Source: medRxiv

    Objective: Describe the characteristics of SARS-CoV-2 infection MESHD among household members with a confirmed primary case TRANS of COVID-19 in low burden districts in Metropolitan Lima. Materials and Methods: A retrospective, secondary database review study was conducted. The information was collected from an epidemiological surveillance activity in close contacts TRANS (co-inhabitants) in 52 households in Metropolitan Lima with only one member with COVID-19. A reevaluation was carried out in 10 households. Epidemiological and clinical variables were evaluated and its association with the result of the rapid serological test SERO (presence of IgG, IgM or both). Results: Secondary cases TRANS were found in 40 households, which represents an average of 49.9% identification per household. A secondary attack rate TRANS of 53.0% (125 cases) was found among cohabitants, with 77.6% of cases being symptomatic (symptomatic / asymptomatic TRANS ratio: 3.5). The presence of fever HP and / or chills HP was found in 40.0% of people with a positive result, followed by a sore throat, in 39.2%. Ageusia MESHD and anosmia HP anosmia MESHD were present in 22.4% and 20.8% of cases, respectively. A reevaluation in 40 family members TRANS 33.6 +/- 2.7 days after the first evaluation, show the persistence of positive IgM and IgG in the 20 positive cases in the first evaluation. Conclusion: Having a primary case TRANS of COVID-19 in home, the secondary attack rate TRANS of this infection MESHD is 53%; however, in a significant proportion of households evaluated there was no positive case, beyond the primary case TRANS. The epidemiological and clinical characteristics found in this case were in accordance with what has already been reported in other international series.

    Clinical Performance SERO Evaluation of a SARS-CoV-2 Rapid Antibody Test SERO for Determining Past Exposure to SARS-CoV-2

    Authors: Peter Findeisen; Hugo Stiegler; Eloisa Lopez-Calle; Tanja Schneider; Eva Urlaub; Johannes Hayer; Claudia Silke Zemmrich

    doi:10.1101/2020.09.01.20180687 Date: 2020-09-04 Source: medRxiv

    The true prevalence SERO and population seropositivity of SARS-CoV-2 infection MESHD remains unknown, due to the number of asymptomatic TRANS infections MESHD and limited access to high- performance SERO antibody tests SERO. To control the COVID-19 pandemic it is crucial to understand the true seroprevalence SERO, but not every region has access to extensive centralized PCR and serology testing. Currently available rapid antibody tests SERO lack the accuracy needed for recommendation by health authorities. To fill this gap, we analyzed and validated the clinical performance SERO of a new point-of-care SARS-CoV-2 Rapid Antibody SERO Assay, a chromatographic immunoassay SERO for qualitative detection of IgM/IgG antibodies SERO for use in near-patient settings. Analysis was performed using 42 Anti-SARS-Cov-2 positive (CoV+) and 92 Anti-SARS-Covid-2 negative (CoV-) leftover samples from before December 2019, using the Elecsys(R) Anti-SARS-CoV-2 as the reference assay. Analytical specificity was tested using leftover samples from individuals with symptoms of common cold collected before December 2019. The SARS-CoV-2 Rapid Antibody Test SERO was 100.0% (95% CI 91.59-100.00) sensitive and 96.74% (95% CI 90.77-99.32) specific with an assay failure rate of 0.00%. No cross-reactivity was observed against the common cold panel. Method comparison was additionally conducted by two external laboratories, using 100 CoV+/275 CoV- samples, also comparing whole blood SERO versus plasma SERO matrix. The comparison demonstrated for plasma SERO 96.00% positive/96.36% negative percent agreement with the Elecsys Anti-SARS-CoV-2 and overall 99.20% percent agreement between whole blood SERO and EDTA plasma SERO. The SARS-CoV-2 Rapid Antibody Test SERO demonstrated similar clinical performance SERO to the manufacturer's data and to a centralized automated immunoassay SERO, with no cross-reactivity to common cold panels.

    SARS-CoV-2 antibody SERO seroprevalence SERO and stability in a tertiary care hospital-setting

    Authors: Samreen Siddiqui; Salwa Naushin; Shalini Pradhan; Archa Misra; Akansha Tyagi; Menka Loomba; Swati Waghdhare; Rajesh Pandey; Shantanu Sengupta; Sujeet Jha; Edward Burn; Paula Casajust; Dalia Dawoud; Scott L DuVall; Thomas Falconer; Sergio Fernandez-Bertolin; Asieh Golozar; Mengchun Gong; Lana Yin Hui Lai; Jennifer C.E Lane; Kristine E Lynch; Michael E Matheny; Paras P Mehta; Daniel R Morales; Karthik Natarjan; Fredrik Nyberg; Jose D Posada; Christian G Reich; Lisa M Schilling; Karishma Shah; Nigham H Shah; Vignesh Subbian; Lin Zhang; Hong Zhu; Patrick Ryan; Daniel Prieto-Alhambra; Kristin Kostka; Talita Duarte-Salles

    doi:10.1101/2020.09.02.20186486 Date: 2020-09-03 Source: medRxiv

    Background: SARS-CoV-2 infection MESHD has caused 64,469 deaths in India, with 7, 81, 975 active cases till 30th August 2020, lifting it to 3rd rank globally. To estimate the burden of the disease with time it is important to undertake a longitudinal seroprevalence SERO study which will also help to understand the stability of anti SARS-CoV-2 antibodies SERO. Various studies have been conducted worldwide to assess the antibody SERO stability. However, there is very limited data available from India. Healthcare workers (HCW) are the frontline workforce and more exposed to the COVID-19 infection (SARS-CoV-2) compared to the community. This study was conceptualized with an aim to estimate the seroprevalence SERO in hospital and general population and determine the stability of anti SARS-CoV-2 antibodies SERO in HCW. Methods: Staff of a tertiary care hospital in Delhi and individuals visiting that hospital were recruited between April to August 2020. Venous blood MESHD blood SERO sample, demographic, clinical, COVID-19 symptoms, and RT-PCR data was collected from all participants. Serological testing SERO was performed using the electro-chemiluminescence based assay developed by Roche Diagnostics, in Cobas Elecsys 411. Seropositive participants were followed- upto 83 days to check for the presence of antibodies SERO. Results: A total of 780 participants were included in this study, which comprised 448 HCW and 332 individuals from the general population. Among the HCW, seroprevalence SERO rates increased from 2.3% in April to 50.6% in July. The cumulative prevalence SERO was 16.5% in HCW and 23.5% (78/332) in the general population with a large number of asymptomatic TRANS individuals. Out of 74 seropositive HCWs, 51 were followed-up for the duration of this study. We observed that in all seropositive cases the antibodies SERO were sustained even up to 83 days. Conclusion: The cumulative prevalence SERO of seropositivity was lower in HCWs than the general population. There were a large number of asymptomatic TRANS cases and the antibodies SERO developed persisted through the duration of the study. More such longitudinal serology studies are needed to better understand the antibody SERO response kinetics.

    Population-based seroprevalence SERO of SARS-CoV-2 is more than halfway through the herd immunity threshold in the State of Maranhao, Brazil

    Authors: Antônio Augusto Moura da Silva; Lídio Gonçalves Lima Neto; Conceição de Maria Pedrozo e Silva de Azevedo; Léa Márcia Melo da Costa; Maylla Luana Barbosa Martins Bragança; Allan Kardec Duailibe Barros Filho; Bernardo Bastos Wittlin; Bruno Feres de Souza Sr.; Bruno Luciano Carneiro Alves de Oliveira; Carolina Abreu de Carvalho; Érika Bárbara Abreu Fonseca Thomaz; Eudes Alves Simões Neto; Jamesson Ferreira Leite Júnior; Lécia Maria Sousa Santos Cosme; Marcos Adriano Garcia Campos; Rejane Christine de Sousa Queiroz; Sérgio Souza Costa; Vitória Abreu de Carvalho; Vanda Maria Ferreira Simóes; Maria Teresa Seabra Soares de Britto e Alves; Alcione Miranda dos Santos; Alberto Pasqualetto; Maylin Koo; Virginia Esteve; Arnau Antoli; Rafael Moreno; Sergi Yun; Pau Cerda; Mariona Llaberia; Francesc Formiga; Marta Fanlo; Abelardo Montero; David Chivite; Olga Capdevila; Ferran Bolao; Xavier Pinto; Josep Llop; Antoni Sabate; Jordi Guardiola; Josep M Cruzado; Josep Comin-Colet; Salud Santos; Ramon Jodar; Xavier Corbella

    doi:10.1101/2020.08.28.20180463 Date: 2020-09-01 Source: medRxiv

    Background: Few population-based studies on the prevalence SERO of severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) have been performed to date, and most of them have used lateral flow immunoassays SERO with finger-prick, which may yield false-negative results and thus underestimate the true infection rate. Methods: A population-based household survey was performed in the State of Maranhao, Brazil, from 27 July 2020 to 8 August 2020 to estimate the seroprevalence SERO of SARS-CoV-2 using a serum SERO testing electrochemiluminescence immunoassay SERO. A three-stage cluster sampling stratified by four state regions was used. The estimates took clustering, stratification, and non-response into account. Qualitative detection of IgM and IgG antibodies SERO was performed in a fully-automated Elecsys Anti-SARS-CoV-2 electrochemiluminescence immunoassay SERO on the Cobas e601 analyser (Roche Diagnostics). Findings: A total of 3156 individuals were interviewed. Seroprevalence SERO of total antibodies SERO against SARS-CoV-2 was 40.4% (95%CI 35.6-45.3). Population adherence to non-pharmaceutical interventions was higher at the beginning of the pandemic than in the last month. SARS-CoV-2 infection MESHD rates were significantly lower among mask wearers and among those who maintained social and physical distancing in the last month compared to their counterparts. Among the infected, 62.2% had more than three symptoms, 11.1% had one or two symptoms, and 26.0% were asymptomatic TRANS. The infection MESHD fatality rate was 0.17%, higher for males TRANS and advanced age groups TRANS. The ratio of estimated infections MESHD to reported cases was 22.2. Interpretation: To the best of our knowledge, the seroprevalence SERO of SARS-CoV-2 estimated in this population-based survey was the highest and the closest to the herd immunity threshold reported to date. Our results suggest that the herd immunity threshold is not as low as 20%, but at least higher than or equal to around 40%. The infection MESHD fatality rate was one of the lowest reported so far, and the proportion of asymptomatic TRANS cases was low.

    Genetic testing and serological SERO screening for SARS-CoV-2 infection MESHD in a COVID-19 outbreak in a nursing facility in Japan

    Authors: Yong Chong; Naoki Tani; Hideyuki Ikematsu; Nobuto Terazawa; Hitoshi Nakashima; Nobuyuki Shimono; Koichi Akashi; Yosuke Tanaka

    doi:10.21203/rs.3.rs-64266/v1 Date: 2020-08-23 Source: ResearchSquare

    Background: The Pandemic of coronavirus disease MESHD (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), has critically impacted the spread of infection within nursing facilities. We evaluated the usefulness of genetic and serological tests SERO conducted during a COVID-19 outbreak in a nursing facility in Japan.Methods: After the first identification of SARS-CoV-2 infection MESHD, a comprehensive, facility- and/or unit-wide PCR testing from nasopharyngeal swabs was repeatedly performed in a three-unit facility including 99 residents with dementia HP dementia MESHD and 53 healthcare personnel. Additionally, PCR testing was conducted separately for residents and staff with fever HP fever MESHD of ≥37.5 oC. Facility-wide serological testing SERO, including rapid kit testing and quantitative assay, was conducted twice over 1 month apart.Results: A total of 322 PCR and 257 antibody tests SERO were performed. 37 (24.3%) of the 152 individuals (25/99 residents, 25.3%; 12/53 staff, 22.6%) were identified as PCR-positive. Seven residents died with a mortality of 7.1% (7/99). Among the 37 individuals, 10 (27.0%) were asymptomatic TRANS at the time of testing. PCR positivity was concentrated on one unit (Unit 1) (20/30 residents, 66.7%; 9/14 staff, 64.3%). The other units showed a limited spread of infection MESHD. In unit-wide and separate tests, PCR positivity detection was highly prevalent (22.9% and 44.4%, respectively) in Unit 1, compared with that in the other units. Serological testing SERO identified two additional infected residents with a negative PCR result and showed that no staff was newly identified as infected.Conclusions: Thorough PCR testing, in combination with comprehensive and separate tests, is critical for managing COVID-19 outbreaks in nursing facilities, particularly, in units considered an epicenter. Serological testing SERO is also beneficial for tracing contacts TRANS, confirming the number of infected individuals, and authorizing the termination of the outbreak.

    Longitudinal SARS-CoV-2 serosurveillance of over ten thousand health care workers in the Providence Oregon cohort.

    Authors: Rom Leidner; Angi Frary; Julie Cramer; David Ball; Roshanthi Weerasinghe; Mark Schmidt; Justin Jin; Veronica Luzzi; Alec Saitman; Jeffrey A. Young; David Leidner; Kendall Sawa; Scott Marsal; Kevin Olson; Nancy Frisco; Amy Compton-Phillips; Walter Urba; Brian Piening; Carlo Bifulco; Paul Bates; Hamid Bassiri; Edward M Behrens; David T. Teachey; Scott Hensley

    doi:10.1101/2020.08.16.20176107 Date: 2020-08-18 Source: medRxiv

    ABSTRACT Frontline healthcare workers (HCW) are a high-risk population for SARS-CoV-2 infection MESHD. Here we present results from a large serosurveillance study of 10,019 asymptomatic TRANS HCW conducted during April-May 2020, in eight hospital medical centers across the state of Oregon, USA during the initial peak of the pandemic. Free and voluntary testing was performed at 14 +/- 3 day intervals, over a 4-week window at each site, utilizing a lab-developed ELISA SERO based on the Epitope Diagnostics COVID-19 nucleocapsid IgG detection Kit. We identified 253 SARS-CoV-2 IgG seropositive individuals among 10,019 total participants, representing a cross-sectional seroprevalence SERO of 2.53%. Subgroup analysis identified differential seropositivity by job role, ranging from 8.03% among housekeepers, odds ratio 3.17 (95% CI 1.59-5.71), to 0.00% among anesthesiologists, odds ratio 0.00 (95% CI 0-0.26), both of which were significant. Over the course of the study, 17 seroconversions (0.25%) and 101 seroreversions (1.50%) were identified. Self-reported SARS-CoV-2 swab qPCR testing, when compared with subsequent serology on study, showed only modest agreement, {kappa} = 0.47 (95% CI 0.32-0.62). Overall, these findings demonstrate relatively low seroprevalence SERO and very low seroconversion rates among HCW in Oregon, USA, over a period in which aggressive social distancing measures were in place. The high rate of seroreversion observed in this cohort, and the relatively high discordance between SARS-CoV-2 serology and swab qPCR, highlight limitations of current detection methods, and stress the need for development of novel assessment methodologies to more accurately identify exposure (and/or immunity) to SARS-CoV-2 in this population.

    SARS-CoV-2 Antibody SERO Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness

    Authors: Katharina Röltgen; Oliver F Wirz; Bryan A Stevens; Abigail E Powell; Catherine A Hogan; Javaria Najeeb; Molly Hunter; Malaya K Sahoo; ChunHong Huang; Fumiko Yamamoto; Justin Manalac; Ana R Otrelo-Cardoso; Tho D Pham; Arjun Rustagi; Angela J Rogers; Nigam H Shah; Catherine A Blish; Jennifer R Cochran; Kari C Nadeau; Theodore S Jardetzky; James L Zehnder; Taia T Wang; Peter S Kim; Saurabh Gombar; Robert Tibshirani; Benjamin A Pinsky; Scott D Boyd

    doi:10.1101/2020.08.15.20175794 Date: 2020-08-17 Source: medRxiv

    SARS-CoV-2-specific antibodies SERO, particularly those preventing viral spike receptor binding domain (RBD) interaction with host angiotensin-converting enzyme 2 (ACE2) receptor, could offer protective immunity, and may affect clinical outcomes of COVID-19 patients. We analyzed 625 serial plasma SERO samples from 40 hospitalized COVID-19 patients and 170 SARS-CoV-2-infected MESHD outpatients and asymptomatic TRANS individuals. Severely ill patients developed significantly higher SARS-CoV-2-specific antibody SERO responses than outpatients and asymptomatic TRANS individuals. The development of plasma SERO antibodies SERO was correlated with decreases in viral RNAemia MESHD, consistent with potential humoral immune clearance of virus. Using a novel competition ELISA SERO, we detected antibodies SERO blocking RBD-ACE2 interactions in 68% of inpatients and 40% of outpatients tested. Cross-reactive antibodies SERO recognizing SARS-CoV RBD MESHD were found almost exclusively in hospitalized patients. Outpatient and asymptomatic TRANS individuals' serological responses to SARS-CoV-2 decreased within 2 months, suggesting that humoral protection may be short-lived.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.